ArticleBMC dermatology2017
Variation of mutant allele frequency in NRAS Q61 mutated melanomas.
Article in BMC dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Wild-type RAS signaling is an essential therapeutic target inScience signaling · 2025Article
- Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens.Science advances · 2024Article
- Structural characterization and AlphaFold modeling of human T cell receptor recognition of NRAS cancer neoantigens.bioRxiv : the preprint server for biology · 2024Article
- Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.Nature communications · 2023Article
- Pathology and Molecular Biology of Melanoma.Current issues in molecular biology · 2023Review
- The genomic landscape across 474 surgically accessible epileptogenic human brain lesions.Brain : a journal of neurology · 2023Article
- Article
- Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.Nature communications · 2022Article
- Review
- The Genetics of Early-Stage Melanoma in a Veteran Population.Frontiers in oncology · 2022Article
- Mitochondrial Metabolism in Melanoma.Cells · 2021Review
- The retrospective molecular analysis of large or giant congenital melanocytic nevi in a group of Polish children.Journal of mother and child · 2021Article
- Review
- Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma.Pigment cell & melanoma research · 2021Article
- Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines.Melanoma research · 2020Article
- The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.The Journal of investigative dermatology · 2020Review
- Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.BMC cancer · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSomatic mutations of BRAF or NRAS activating the MAP kinase cell signaling pathway are present in 70% of cutaneous melanomas. The mutant allele frequency of BRAF V600E (M%BRAF) was recently shown to be highly heterogeneous in melanomas. The present study focuses on the NRAS Q61 mutant allele frequency (M%NRAS).
methodsRetrospective quantitative analyze of 104 NRAS mutated melanomas was performed using pyrosequencing. Mechanisms of M%NRAS imbalance were studied by fluorescence in situ hybridization (FISH) and microsatellite analysis.
resultsM%NRAS was increased in 27.9% of cases. FISH revealed that chromosome 1 instability was the predominant mechanism of M%NRAS increase, with chromosome 1 polysomy observed in 28.6% of cases and intra-tumor cellular heterogeneity with copy number variations of chromosome 1/NRAS in 23.8%. Acquired copy-neutral loss of heterozygosity (LOH) was less frequent (19%). However, most samples with high M%NRAS had only one copy of NRAS locus surrounding regions suggesting a WT allele loss. Clinical characteristics and survival of patients with either <60% or ≥60% of M%NRAS were not different.
conclusionAs recently shown for M%BRAF, M%NRAS is highly heterogeneous. The clinical impacts of high M%NRAS should be investigated in a larger series of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.